Gilead Sciences reports $8.3 billion revenue for quarter ended September 30, 2026, up 6.8%
Gilead Sciences reported revenue of $8.3 billion for the quarter ended September 30, 2026, an increase of 6.8% from the same quarter a year earlier ($7.77 billion).
For the same period it posted net income of $2.43 billion, down 20.4%, or $1.94 per diluted share (2.43 a year earlier).
That is a net margin of 29.3%.
On Sanad's AAOIFI Standard 21 screen, Gilead Sciences is currently compliant: interest-bearing debt is 12.4% of market capitalisation (limit 30%), and impure income is 1.2% of revenue (limit 5%).
Is Gilead Sciences halal?
See the full AAOIFI screening of Gilead Sciences
See the full AAOIFI screening of Gilead Sciences
Source: 10-Q filed with the U.S. Securities and Exchange Commission on October 30, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.